Published articles

Published articles 1 records found  Search took 0.01 seconds. 
1.
8 p, 207.5 KB Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer / Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ; Cervantes, Andrés (Universitat de València. Biomedical Research Institute) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Roselló, Susana (Universitat de València. Biomedical Research Institute) ; Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Tejpar, Sabine (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Prenen, H. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Martinelli, E. (Second University of Naples. Department of Experimental and Clinical Medicine) ; Troiani, T. (Second University of Naples. Department of Experimental and Clinical Medicine) ; Laffranchi, B. (Merck Serono SA) ; Jego, V (Merck Serono SA) ; von Richter, O. (Merck KGaA) ; Ciardiello, Fortunato (Second University of Naples. Department of Experimental and Clinical Medicine) ; Universitat Autònoma de Barcelona
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. [...]
2015 - 10.1038/bjc.2015.144
British Journal of Cancer, Vol. 112 (June 2015) , p. 1874-1881  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.